GSK (GSK) Stock Forecast & Price Target

Q: What analysts cover GSK?

GSK has been rated by research analysts at Berenberg Bank , Deutsche Bank Aktiengesellschaft , Jefferies Financial Group , and Royal Bank Of Canada in the past 90 days.

GBX 1,831.75 +7.25 (+0.40%)

As of 06:18 AM Eastern

Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
1

Hold
5

Buy
2

Based on 8 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 1 has given a sell rating, 5 have given a hold rating, and 2 have given a buy rating for GSK.

Consensus Price Target

GBX 2,064.38

According to the 8 analysts' twelve-month price targets for GSK, the average price target is GBX 2,064.38. The highest price target for GSK is GBX 2,500, while the lowest price target for GSK is GBX 1,500. The average price target represents a forecasted upside of 12.70% from the current price of GBX 1,831.75.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

Type	Current Forecast 11/3/25 to 11/3/26	1 Month Ago 10/4/25 to 10/4/26	3 Months Ago 8/5/25 to 8/5/26	1 Year Ago 11/3/24 to 11/3/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 2,064.38	GBX 2,064.38	GBX 2,048.57	GBX 1,730
Consensus Rating	Hold	Hold	Hold	Hold

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Healthcare Companies
Consensus Rating Score	2.13	2.32
Consensus Rating	Hold	Hold
News Sentiment Rating	Neutral News See Recent GSK News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Action	Rating	Price Target	Report Date Upside/Downside
10/29/2026	Deutsche Bank Aktiengesellschaft 3 of 5 stars	Reiterated Rating	Hold	GBX 2,000	+10.77%
10/20/2026	Jefferies Financial Group 3 of 5 stars	Reiterated Rating	Buy	GBX 2,500	+34.34%
9/15/2026	Berenberg Bank 3 of 5 stars	Boost Target	Hold	GBX 2,000 ➝ GBX 2,200	+18.38%
9/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Sector perform	GBX 1,975	+9.57%
5/6/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Target	Neutral	GBX 2,250 ➝ GBX 2,100	+12.06%
3/25/2026	Shore Capital Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
1/23/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	GBX 1,940	+7.51%
1/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:37 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 31, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc reported third-quarter revenue of approximately £8.9 billion, with core operating profit and core earnings per share modestly exceeding analyst expectations, driven by growth in specialty medicines and newer products.
The company plans to nearly double the number of cancer medicines in clinical trials next year, supporting its longer-term pipeline and growth prospects as its strategy gains traction.
GSK plc currently trades at $1,850.00, which is below the consensus price target of GBX 2,064.38, suggesting potential upside for investors despite recent volatility.
Insiders have shown confidence in the company, with multiple purchases recorded in recent months, including Jonathan Symonds buying 1,500 shares and Anne Beal purchasing 637 shares in September 2026.
The stock offers a dividend yield of 3.75%, providing a steady income stream for investors while the company maintains a low beta of 0.28, indicating lower volatility compared to the broader market.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

Vaccine revenue fell 2% in the third quarter, with key brands Shingrix down 5% and Arexvy down 24%, raising concerns about demand for these critical products.
A £328 million restructuring charge connected with the Accelerate Growth program contributed to a 16% decline in reported operating profit and a 21% fall in total earnings per share, making headline profit figures less attractive.
GSK plc reaffirmed its 2026 outlook for 3% to 5% turnover growth and 7% to 9% growth in core operating profit, which may disappoint investors who were looking for a stronger outlook following the earnings beat.
The stock recently broke below its 50-day moving average of GBX 1,849.02, signaling potential short-term weakness in momentum and investor sentiment.
Higher financing costs weighed on reported results, further impacting the company's bottom line and overall financial performance despite the underlying revenue beat.

GSK Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 2,064.38, with a high forecast of GBX 2,500 and a low forecast of GBX 1,500.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There is currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 12.70% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and Royal Bank Of Canada in the past 90 days.

Analysts like GSK less than other "healthcare" companies. The consensus rating score for GSK is 2.13 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

MarketBeat monitors more than a dozen sources for GSK analyst ratings, with the most recent rating issued on 10/29/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target